Sorry, you need to enable JavaScript to visit this website.

CARDURA® (XL) (doxazosin mesylate extended release tablets) Clinical Studies

14 CLINICAL STUDIES

14.1 Studies in Patients with BPH

Two controlled clinical studies were conducted with CARDURA XL in BPH patients, followed by an open-label extension study. Study 1 was a randomized, double-blind, parallel-group, placebo- and active-controlled study that compared the safety and efficacy of CARDURA XL (4 or 8 mg/day) with that of doxazosin IR (1, 2, 4, or 8 mg/day) and placebo over 13 weeks in 795 BPH patients, of whom 317 were randomized to CARDURA XL. Study 2 was a randomized, double-blind, parallel-group, active-controlled study that compared the safety and efficacy of CARDURA XL (4 or 8 mg/day) with that of doxazosin IR (1, 2, 4, or 8 mg/day) over 13 weeks in 680 BPH patients, of whom 350 were randomized to CARDURA XL.

In both studies, men aged 50–80 years with symptomatic benign prostatic hyperplasia (BPH) were enrolled. Symptomatic BPH was defined as a total score of at least 12 points on the 35-point International Prostate Symptom Score (IPSS) and a maximum urinary flow rate of ≤ 15 mL/sec but no less than 5 mL/sec (total voided volume ≥ 150 mL). In these two studies, conducted in a total of 1475 patients, the mean age was 64 years (range 47–83 years). Patients were Caucasian (96%), Black (1.5%), Asian (1.5%), and of Other ethnicity (1%).

In both studies, CARDURA XL dosing was initiated after a 2 week placebo run-in period at 4 mg per day increasing to 8 mg per day after 7 weeks of treatment if adequate response (defined as having both an increase in maximum urinary flow rate of at least 3 mL/sec and a decrease in total IPSS of at least 30% from baseline) was not seen. Doxazosin IR was titrated from an initial dose of 1 mg daily to 2 mg daily after 1 week with the option to increase to 4 mg daily after 3 weeks and then to a maximum of 8 mg daily after 7 weeks if an adequate response was not seen. The final daily dose of CARDURA XL was 4 mg in 43% of patients and 8 mg in 57% of patients. The final daily dose of doxazosin IR was 1 mg in 1%, 2 mg in 12%, 4 mg in 30%, and 8 mg in 57% of patients.

There were two primary efficacy variables in each of these two controlled clinical studies: the total International Prostate Symptom Score (IPSS) and the peak urinary flow rate (Qmax). The IPSS consists of seven questions that assess the severity of both irritative (frequency, urgency, nocturia) and obstructive (incomplete emptying, stopping and starting, weak stream, and pushing or straining) symptoms, with possible total scores ranging from 0 to 35. The Qmax was measured in both studies just prior to the next dose. The results for total symptom score are given in Table 3, and for maximum urinary flow rate in Table 4.

TABLE 3 TOTAL INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS)*
N MEAN
BASELINE (±SD)
MEAN CHANGE (±SE)
*
Derived from IPSS questionnaire (range 0–35)
Mean change from baseline to Week 13
Statistically significant difference (p <0.001) vs. placebo
STUDY 1
Placebo 151 17.9 ± 4.3 -6.1 ± 0.41
CARDURA XL 310 17.7 ± 4.3 -8.0 ± 0.30
Doxazosin IR 311 17.8 ± 4.5 -8.4 ± 0.29
STUDY 2
CARDURA XL 330 18.4 ± 5.0 -8.1 ± 0.30
Doxazosin IR 313 18.4 ± 4.8 -7.9 ± 0.31
TABLE 4 MAXIMUM FLOW RATE (mL/sec)
N MEAN
BASELINE (±SD)
MEAN CHANGE (±SE)*
*
Mean change from baseline to Week 13
Statistically significant difference (p <0.001) vs. placebo
STUDY 1
Placebo 151 9.8 ± 2.6 0.8 ± 0.32
CARDURA XL 300 10.3 ± 2.6 2.6 ± 0.24
Doxazosin IR 303 10.1 ± 2.7 2.2 ± 0.23
STUDY 2
CARDURA XL 322 10.5 ± 2.6 2.7 ± 0.27
Doxazosin IR 314 10.6 ± 2.6 2.7 ± 0.27

Mean changes in IPSS scores for CARDURA XL and placebo in Study 1 are summarized in Figure 2.

Figure 2

Mean changes in maximum urinary flow rate (Qmax) for both CARDURA XL and placebo in Study 1 are summarized in Figure 3.

Figure 3

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Report an Adverse Event
1-800-438-1985

Search

Please enter your search term(s) for CARDURA® XL

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.